Systemic sclerosis: A critical digest of the recent literature

Clinical and Experimental Rheumatology

Volumn 33, Issue , 2015, Pages 3-14

  Barsotti, Simone ^a   Stagnaro, Chiara ^a   Della Rossa, Alessandra ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Literature; Review; Systemic sclerosis

Indexed keywords

AMBRISENTAN; AUTOANTIBODY; AZATHIOPRINE; BOSENTAN; CYCLOPHOSPHAMIDE; FRESOLIMUMAB; IMATINIB; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; MACITENTAN; MYCOPHENOLATE MOFETIL; RIOCIGUAT; RITUXIMAB; SILDENAFIL; TOCILIZUMAB;

AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; GASTROINTESTINAL DISEASE; HEART DISEASE; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MUSCULOSKELETAL DISEASE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; REVIEW; SKIN DISEASE; SYSTEMIC SCLEROSIS; VASCULAR DISEASE; ANIMAL; CLASSIFICATION; DISEASE COURSE; PREDICTIVE VALUE; PROGNOSIS; RISK FACTOR; SCLERODERMA, SYSTEMIC;

ANIMALS; DISEASE PROGRESSION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK FACTORS; SCLERODERMA, SYSTEMIC;

EID: 84946235657     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Review

References (147)

1. TYNDALL A, TYRRELL KENNEDY A, ALLANORE Y, KHANNA D: Clinical and experimental scleroderma 2014. Clin Exp Rheumatol 2014; 32 (Suppl. 86): S-3.
2. BARSOTTI S, BELLANDO RANDONE S, GUIDUCCI S, DELLA ROSSA A: Systemic sclerosis: a critical digest of the recent literature. Clin Exp Rheumatol 2014; 32 (Suppl. 86): S194-205.
3. Van den HOOGEN F, KHANNA D, FRANSEN J et al.: 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum 2013; 65: 2737-47.
4. ALHAJERI H, HUDSON M, FRITZLER M et al.: 2013 American College of Rheumatology/European League against rheumatism classification criteria for systemic sclerosis outperform the 1980 criteria: data from the Canadian Scleroderma Research Group. Arthritis Care Res 2015; 67: 582-7.
5. JORDAN S, MAURER B, TONIOLO M, MICHEL B, DISTLER O: Performance of the new ACR/EULAR classification criteria for systemic sclerosis in clinical practice. Rheumatology (Oxford) 2015; 54: 1454-8.
6. AVOUAC J, FRANSEN J, WALKER UA et al.: Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group. Ann Rheum Dis 2011; 70: 476-81.
7. MINIER T, GUIDUCCI S, BELLANDO-RANDONE S et al.: Preliminary analysis of the very early diagnosis of systemic sclerosis (VEDOSS) EUSTAR multicentre study: evidence for puffy fingers as a pivotal sign for suspicion of systemic sclerosis. Ann Rheum Dis 2014; 73: 2087-93.
8. VALENTINI G, MARCOCCIA A, CUOMO G, IUDICI M, VETTORI S: The concept of early systemic sclerosis following 2013 ACR\ EULAR criteria for the classification of systemic sclerosis. Curr Rheumatol Rev 2014; 10: 38-44.
9. VALENTINI G: Undifferentiated Connective Tissue Disease at risk for systemic sclerosis (SSc) (so far referred to as very early/early SSc or pre-SSc). Autoimmun Rev 2015 Mar; 14: 210-3.
10. PATTANAIK D, BROWN M, POSTLETHWAITE BC, POSTLETHWAITE AE: Pathogenesis of Systemic Sclerosis. Front Immunol 2015; 6: 272.
11. ZOCHLING J, NEWELL F, CHARLESWORTH JC et al.: An Immunochip-based interrogation of scleroderma susceptibility variants identifies a novel association at DNASE1L3. Arthritis Res Ther 2014; 16: 438.
12. LóPEZ-ISAC E, BOSSINI-CASTILLO L, GUERRA SG et al.: Identification of IL12RB1 as a novel systemic sclerosis susceptibility locus. Arthritis Rheumatol (Hoboken NJ) 2014; 66: 3521-3.
13. FERRI C, GIUGGIOLI D, COLACI M: Viral infections and systemic sclerosis. Clin Exp Rheumatol 2014; 32 (Suppl. 86): S-229.
14. MASTROFRANCESCO A, ALFE M, ROSATO E et al.: Proinflammatory effects of diesel exhaust nanoparticles on scleroderma skin cells. J Immunol Res 2014; 2014: 138751.
15. HUGHES M, COOPER GJS, WILKINSON J, NEW P, GUY JM, HERRICK AL: Abnormalities of selenium but not of copper homeostasis may drive tissue fibrosis in patients with systemic sclerosis. Rheumatology (Oxford) 2015; 54: 747-8.
16. BEYER C, SCHETT G, DISTLER O, DISTLER JHW: Animal models of systemic sclerosis: prospects and limitations. Arthritis Rheum 2010; 62: 2831-44.
17. MANETTI M, ROSA I, MILIA AF et al.: Inactivation of urokinase-type plasminogen activator receptor (uPAR) gene induces dermal and pulmonary fibrosis and peripheral microvasculopathy in mice: a new model of experimental scleroderma? Ann Rheum Dis 2014; 73: 1700-9.
18. SHIRAI Y, OKAZAKI Y, INOUE Y et al.: Elevated levels of pentraxin 3 in systemic sclerosis: associations with vascular manifestations and defective vasculogenesis. Arthritis Rheumatol (Hoboken NJ.) 2015; 67: 498-507.
19. MAURER B, DISTLER A, SULIMAN YA et al.: Vascular endothelial growth factor aggravates fibrosis and vasculopathy in experimental models of systemic sclerosis. Ann Rheum Dis 2014; 73: 1880-7.
20. CIPRIANI P, Di BENEDETTO P, CAPECE D et al.: Impaired Cav-1 expression in SSc mesenchymal cells upregulates VEGF signaling: a link between vascular involvement and fibrosis. Fibrogenesis Tissue Repair 2014; 7: 13.
21. LONATI PA, BREMBILLA NC, MONTANARI E et al.: High IL-17E and low IL-17C dermal expression identifies a fibrosis-specific motif common to morphea and systemic sclerosis. PloS One 2014; 9: e105008.
22. KUDO H, JINNIN M, ASANO Y et al.: Decreased interleukin-20 expression in scleroderma skin contributes to cutaneous fibrosis. Arthritis Rheumatol (Hoboken NJ.) 2014; 66: 1636-47.
23. Van PRAET JT, DONOVAN E, VANASSCHE I et al.: Commensal microbiota influence systemic autoimmune responses. EMBO J 2015; 34: 466-74.
24. TOMCIK M, ZERR P, PITKOWSKI J et al.: Heat shock protein 90 (Hsp90) inhibition targets canonical TGF-β signalling to prevent fibrosis. Ann Rheum Dis 2014; 73: 1215-22.
25. AVOUAC J, PALUMBO-ZERR K, RUZEHAJI N et al.: The nuclear receptor constitutive androstane receptor/NR1I3 enhances the profibrotic effects of transforming growth factor β and contributes to the development of experimental dermal fibrosis. Arthritis Rheumatol (Hoboken NJ.) 2014; 66: 3140-50.
26. LIANG M, LV J, ZOU L et al.: A modified murine model of systemic sclerosis: bleomycin given by pump infusion induced skin and pulmonary inflammation and fibrosis. Lab Investig J Tech Methods Pathol 2015; 95: 342-50.
27. ZHANG L, YAN J-W, WANG Y-J et al.: Association of interleukin 1 family with systemic sclerosis. Inflammation 2014; 37: 1213-20.
28. MARTíNEZ-GODíNEZ MA, CRUZ-DOMíNGUEZ MP, JARA LJ et al.: Expression of NLRP3 inflammasome, cytokines and vascular mediators in the skin of systemic sclerosis patients. Isr Med Assoc J 2015; 17: 5-10.
29. DESALLAIS L, AVOUAC J, FRéCHET M et al.: Targeting IL-6 by both passive or active immunization strategies prevents bleomycin-induced skin fibrosis. Arthritis Res Ther 2014; 16: R157.
30. GüNTHER J, KILL A, BECKER MO et al.: Angiotensin receptor type 1 and endothelin receptor type A on immune cells mediate migration and the expression of IL-8 and CCL18 when stimulated by autoantibodies from systemic sclerosis patients. Arthritis Res Ther 2014; 16: R65.
31. PONTICOS M, PAPAIOANNOU I, XU S et al.: Failed degradation of JunB contributes to overproduction of type I collagen and development of dermal fibrosis in patients with systemic sclerosis. Arthritis Rheumatol (Hoboken NJ.) 2015; 67: 243-53.
32. SHIWEN X, STRATTON R, NIKITOROWICZBUNIAK J et al.: A role of Myocardin Related Transcription Factor-A (MRTF-A) in scleroderma related fibrosis. PloS One 2015; 10: e0126015.
33. DISTLER A, LANG V, Del VECCHIO T et al.: Combined inhibition of morphogen pathways demonstrates additive antifibrotic effects and improved tolerability. Ann Rheum Dis 2014; 73: 1264-8.
34. DEES C, SCHLOTTMANN I, FUNKE R et al.: The Wnt antagonists DKK1 and SFRP1 are downregulated by promoter hypermethylation in systemic sclerosis. Ann Rheum Dis 2014; 73: 1232-9.
35. SVEGLIATI S, MARRONE G, PEZONE A et al.: Oxidative DNA damage induces the ATMmediated transcriptional suppression of the Wnt inhibitor WIF-1 in systemic sclerosis and fibrosis. Sci Signal 2014; 7: ra84.
36. MAKINO K, JINNIN M, MAKINO T et al.: Serum levels of soluble carbonic anhydrase IX are decreased in patients with diffuse cutaneous systemic sclerosis compared to those with limited cutaneous systemic sclerosis. Biosci Trends 2014; 8: 144-8.
37. ARNSON Y, AMITAL H, AGMON-LEVIN N et al.: Serum 25-OH vitamin D concentrations are linked with various clinical aspects in patients with systemic sclerosis: a retrospective cohort study and review of the literature. Autoimmun Rev 2011; 10: 490-4.
38. CARAMASCHI P, Dalla GASSA A, RUZZENENTE O et al.: Very low levels of vitamin D in systemic sclerosis patients. Clin Rheumatol 2010; 29: 1419-25.
39. SZODORAY P, NAKKEN B, GAAL J et al.: The complex role of vitamin D in autoimmune diseases. Scand J Immunol 2008; 68: 261-9.
40. ZERR P, VOLLATH S, PALUMBO-ZERR K et al.: Vitamin D receptor regulates TGF-β signalling in systemic sclerosis. Ann Rheum Dis 2015; 74: e20.
41. USATEGUI A, CRIADO G, Del REY MJ, FARé R, PABLOS JL: Topical vitamin D analogue calcipotriol reduces skin fibrosis in experimental scleroderma. Arch Dermatol Res 2014; 306: 757-61.
42. BECKER MO, KILL A, KUTSCHE M et al.: Vascular receptor autoantibodies in pulmonary arterial hypertension associated with systemic sclerosis. Am J Respir Crit Care Med 2014; 190: 808-17.
43. BOURJI KI, KHAIR RM, DAMICO RL, KOLB TM, MATHAI SC, HASSOUN PM: Vascular receptor autoantibodies in pulmonary arterial hypertension. Am J Respir Crit Care Med 2015; 191: 602.
44. BOIN F, ERRE GL, POSADINO AM et al.: Oxidative stress-dependent activation of collagen synthesis is induced in human pulmonary smooth muscle cells by sera from patients with scleroderma-associated pulmonary hypertension. Orphanet J Rare Dis 2014; 9: 123.
45. GILBANE AJ, DERRETT-SMITH E, TRINDER SL et al.: Impaired bone morphogenetic protein receptor II signaling in a transforming growth factor-β-dependent mouse model of pulmonary hypertension and in systemic sclerosis. Am J Respir Crit Care Med 2015; 191: 665-77.
46. DOMSIC RT: Scleroderma: the role of serum autoantibodies in defining specific clinical phenotypes and organ system involvement. Curr Opin Rheumatol 2014; 26: 646-52.
47. SAIGUSA R, ASANO Y, NAKAMURA K et al.: Association of anti-RNA polymerase III antibody and malignancy in Japanese patients with systemic sclerosis. J Dermatol 2015; 42: 524-7.
48. MOINZADEH P, FONSECA C, HELLMICH M et al.: Association of anti-RNA polymerase III autoantibodies and cancer in scleroderma. Arthritis Res Ther 2014; 16: R53.
49. HUDSON M, POPE J, MAHLER M et al.: Clinical significance of antibodies to Ro52/TRIM21 in systemic sclerosis. Arthritis Res Ther 2012; 14: R50.
50. SáNCHEZ-MONTALVá A, FERNáNDEZLUQUE A, SIMEóN CP et al.: Anti-SSA/Ro52 autoantibodies in scleroderma: results of an observational, cross-sectional study. Clin Exp Rheumatol 2014; 32 (Suppl. 86): S177-82.
51. MASSIE C, HUDSON M, TATIBOUET S et al.: Absence of an association between anti-Ro antibodies and prolonged QTc interval in systemic sclerosis: a multicenter study of 689 patients. Semin Arthritis Rheum 2014; 44: 338-44.
52. HUDSON M, SATOH M, CHAN JYF et al.: Prevalence and clinical profiles of "autoantibody-negative" systemic sclerosis subjects. Clin Exp Rheumatol 2014; 32 (Suppl. 86): S127-32.
53. MAHLER M, SATOH M, HUDSON M et al.: Autoantibodies to the Rpp25 component of the Th/To complex are the most common antibodies in patients with systemic sclerosis without antibodies detectable by widely available commercial tests. J Rheumatol 2014; 41: 1334-43.
54. D'AOUST J, HUDSON M, TATIBOUET S et al.: Clinical and serologic correlates of anti-PM/Scl antibodies in systemic sclerosis: a multicenter study of 763 patients. Arthritis Rheumatol (Hoboken NJ.) 2014; 66: 1608-15.
55. CLEMENTS PJ, HURWITZ EL, WONG WK et al.: Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trial. Arthritis Rheum 2000; 43: 2445-54.
56. WIESE AB, BERROCAL VJ, FURST DE et al.: Correlates and responsiveness to change of measures of skin and musculoskeletal disease in early diffuse systemic sclerosis. Arthritis Care Res 2014; 66: 1731-9.
57. VINET É, BERNATSKY S, HUDSON M, PINEAU CA, Baron M, Canadian Scleroderma Research Group: Effect of menopause on the modified Rodnan skin score in systemic sclerosis. Arthritis Res Ther 2014; 16: R130.
58. MAURER B, GRAF N, MICHEL BA et al.: Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database. Ann Rheum Dis 2015; 74: 1124-31.
59. AVOUAC J, WALKER UA, HACHULLA E et al.: Joint and tendon involvement predict disease progression in systemic sclerosis: a EUSTAR prospective study. Ann Rheum Dis 2014 Aug 27 [Epub ahead of print].
60. BáLINT Z, FARKAS H, FARKAS N et al.: A three-year follow-up study of the development of joint contractures in 131 patients with systemic sclerosis. Clin Exp Rheumatol 2014; 32 (Suppl. 86): S68-74.
61. MADDALI-BONGI S, Del ROSSO A, MIKHAYLOVA S et al.: Impact of hand and face disabilities on global disability and quality of life in systemic sclerosis patients. Clin Exp Rheumatol 2014; 32 (Suppl. 86): S15-20.
62. CHUNG L, VALENZUELA A, FIORENTINO D et al.: Validation of a novel radiographic scoring system for calcinosis affecting the hands of patients with systemic sclerosis. Arthritis Care Res 2015; 67: 425-30.
63. OMAIR MA, PAGNOUX C, MCDONALDBLUMER H, JOHNSON SR: Low bone density in systemic sclerosis. A systematic review. J Rheumatol 2013; 40: 1881-90.
64. OMAIR MA, McDONALD-BLUMER H, JOHNSON SR: Bone disease in systemic sclerosis: outcomes and associations. Clin Exp Rheumatol 2014; 32 (Suppl. 86): S28-32.
65. KAHALEH MB: Raynaud phenomenon and the vascular disease in scleroderma. Curr Opin Rheumatol 2004; 16: 718-22.
66. FLAVAHAN NA: Regulation of vascular reactivity in scleroderma: new insights into Raynaud's phenomenon. Rheum Dis Clin North Am 2008; 34: 81-7; vii.
67. CHORA I, GUIDUCCI S, MANETTI M et al.: Vascular biomarkers and correlation with peripheral vasculopathy in systemic sclerosis. Autoimmun Rev 2015; 14: 314-22.
68. CUTOLO M, SULLI A, SMITH V: Assessing microvascular changes in systemic sclerosis diagnosis and management. Nat Rev Rheumatol 2010; 6: 578-87.
69. GHIZZONI C, SEBASTIANI M, MANFREDI A et al.: Prevalence and evolution of scleroderma pattern at nailfold videocapillaroscopy in systemic sclerosis patients: Clinical and prognostic implications. Microvasc Res 2015; 99: 92-5.
70. YALCINKAYA Y, PEHLIVAN O, OMMA A et al.: The relationship between nailfold capillaroscopic assessment and telangiectasia score with severity of peripheral vascular involvement in systemic sclerosis. Clin Exp Rheumatol 2015; 33 (Suppl. 91): S92-97.
71. WALKER UA, TYNDALL A, CZIRJáK L et al.: Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. Ann Rheum Dis 2007; 66: 754-63.
72. SEBASTIANI M, MANFREDI A, CASSONE G, GIUGGIOLI D, GHIZZONI C, FERRI C: Measuring microangiopathy abnormalities in systemic sclerosis patients: the role of capillaroscopy-based scoring models. Am J Med Sci 2014; 348: 331-6.
73. MANFREDI A, SEBASTIANI M, CARRARO V et al.: Prediction risk chart for scleroderma digital ulcers: a composite predictive model based on capillaroscopic, demographic and clinico-serological parameters. Clin Hemorheol Microcirc 2015; 59: 133-43.
74. BRUNI C, GUIDUCCI S, BELLANDO-RANDONE S et al.: Digital ulcers as a sentinel sign for early internal organ involvement in very early systemic sclerosis. Rheumatology (Oxford) 2015; 54: 72-6.
75. ZHANG S, XU D, LI M et al.: Telangiectasia as a potential clinical marker of microvascular lesions in systemic sclerosis patients from EUSTAR data in China. Clin Exp Rheumatol 2015; 33 (Suppl. 91): S106-110.
76. SILVA I, ALMEIDA J, VASCONCELOS C: A PRISMA-driven systematic review for predictive risk factors of digital ulcers in systemic sclerosis patients. Autoimmun Rev 2015; 14: 140-52.
77. ROSATO E, BARBANO B, GIGANTE A et al.: Increased intrarenal arterial stiffness may predict the occurrence of new digital ulcers in systemic sclerosis. Arthritis Care Res 2014; 66: 1380-5.
78. SULLI A, RUARO B, CUTOLO M: Evaluation of blood perfusion by laser speckle contrast analysis in different areas of hands and face in patients with systemic sclerosis. Ann Rheum Dis 2014; 73: 2059-61.
79. RUARO B, SULLI A, ALESSANDRI E, PIZZORNI C, FERRARI G, CUTOLO M: Laser speckle contrast analysis: a new method to evaluate peripheral blood perfusion in systemic sclerosis patients. Ann Rheum Dis 2014; 73: 1181-5.
80. GAILLARD-BIGOT F, ROUSTIT M, BLAISE S et al.: Abnormal amplitude and kinetics of digital postocclusive reactive hyperemia in systemic sclerosis. Microvasc Res 2014; 94: 90-5.
81. BLAISE S, ROUSTIT M, CARPENTIER P, SEINTURIER C, IMBERT B, CRACOWSKI JL: The digital thermal hyperemia pattern is associated with the onset of digital ulcerations in systemic sclerosis during 3 years of followup. Microvasc Res 2014; 94: 119-22.
82. MEIJS J, VOSKUYL AE, BLOEMSAATMINEKUS JPJ, VONK MC: Blood flow in the hands of a predefined homogeneous systemic sclerosis population: the presence of digital ulcers and the improvement with bosentan. Rheumatology (Oxford) 2015; 54: 262-9.
83. CUTOLO M, RUARO B, PIZZORNI C et al.: Longterm treatment with endothelin receptor antagonist bosentan and iloprost improves fingertip blood perfusion in systemic sclerosis. J Rheumatol 2014; 41: 881-6.
84. GUIDUCCI S, BELLANDO RANDONE S, BRUNI C et al.: Bosentan fosters microvascular de-remodelling in systemic sclerosis. Clin Rheumatol 2012; 31: 1723-5.
85. ROMANO E, BELLANDO-RANDONE S, MANETTI M et al.: Bosentan blocks the antiangiogenic effects of sera from systemic sclerosis patients: an in vitro study. Clin Exp Rheumatol 2015; 33 (Suppl. 91): S148-152.
86. FERRI C, SEBASTIANI M, Lo MONACO A et al.: Systemic sclerosis evolution of disease pathomorphosis and survival. Our experience on Italian patients' population and review of the literature. Autoimmun Rev 2014; 13: 1026-34.
87. FISCHER A, SWIGRIS JJ, BOLSTER MB et al.: Pulmonary hypertension and interstitial lung disease within PHAROS: impact of extent of fibrosis and pulmonary physiology on cardiac haemodynamic parameters. Clin Exp Rheumatol 2014; 32 (Suppl. 86): S109-14.
88. BLANCO I, MATHAI S, SHAFIQ M et al.: Severity of systemic sclerosis-associated pulmonary arterial hypertension in African Americans. Medicine (Baltimore) 2014; 93: 177-85.
89. REESE C, PERRY B, HEYWOOD J et al.: Caveolin-1 deficiency may predispose African Americans to systemic sclerosis-related interstitial lung disease. Arthritis Rheumatol (Hoboken NJ.) 2014; 66: 1909-19.
90. SEGAWA S, GOTO D, HORIKOSHI M et al.: Involvement of CD161+ Vδ1+ γδ T cells in systemic sclerosis: association with interstitial pneumonia. Rheumatology (Oxford) 2014; 53: 2259-69.
91. FRAUENFELDER T, WINKLEHNER A, NGUYEN TDL et al.: Screening for interstitial lung disease in systemic sclerosis: performance of high-resolution CT with limited number of slices: a prospective study. Ann Rheum Dis 2014; 73: 2069-73.
92. SALAFFI F, CAROTTI M, BOSELLO S et al.: Computer-aided quantification of interstitial lung disease from high resolution computed tomography images in systemic sclerosis: correlation with visual reader-based score and physiologic tests. BioMed Res Int 2015; 2015: 834262.
93. SPERANDEO M, CATA AD, MOLINARO F et al.: Ultrasound signs of pulmonary fibrosis in systemic sclerosis as timely indicators for chest computed tomography. Scand J Rheumatol 2015 23;1-10.
94. GUARNIERI G, ZANATTA E, MASON P et al.: Determinants of impairment in lung diffusing capacity in patients with systemic sclerosis. Clin Exp Rheumatol 2015; 33 (Suppl. 91): S80-86.
95. HERZOG EL, MATHUR A, TAGER AM, FEGHALI-BOSTWICK C, SCHNEIDER F, VARGA J: Review: interstitial lung disease associated with systemic sclerosis and idiopathic pulmonary fibrosis: how similar and distinct? Arthritis Rheumatol (Hoboken NJ.) 2014; 66: 1967-78.
96. VOLKMANN ER, SAGGAR R, KHANNA D et al.: Improved transplant-free survival in patients with systemic sclerosis-associated pulmonary hypertension and interstitial lung disease. Arthritis Rheumatol (Hoboken NJ.) 2014; 66: 1900-8.
97. NIHTYANOVA SI, SCHREIBER BE, ONG VH et al.: Prediction of pulmonary complications and long-term survival in systemic sclerosis. Arthritis Rheumatol (Hoboken NJ.) 2014; 66: 1625-35.
98. WINSTONE TA, ASSAYAG D, WILCOX PG et al.: Predictors of mortality and progression in scleroderma-associated interstitial lung disease: a systematic review. Chest 2014; 146: 422-36.
99. HUANG J, LI M, TIAN Z et al.: Clinical and laboratory characteristics of systemic sclerosis patients with pulmonary arterial hypertension in China. Clin Exp Rheumatol 2014; 32 (Suppl. 86): S115-21.
100. ROSATO E, ROMANIELLO A, MAGRÌ D et al.: Exercise tolerance in systemic sclerosis patients without pulmonary impairment: correlation with clinical variables. Clin Exp Rheumatol 2014; 32 (Suppl. 86): S103-8.
101. NINABER MK, HAMERSMA WBGJ, SCHOUFFOER AA et al.: Detection of pulmonary vasculopathy by novel analysis of oxygen uptake in patients with systemic sclerosis: association with pulmonary arterial pressures. Clin Exp Rheumatol 2014; 32 (Suppl. 86): S60-7.
102. CHUNG L, FARBER HW, BENZA R et al.: Unique predictors of mortality in patients with pulmonary arterial hypertension associated with systemic sclerosis in the REVEAL registry. Chest 2014; 146: 1494-504.
103. RAJARAM S, SWIFT AJ, CONDLIFFE R et al.: CT features of pulmonary arterial hypertension and its major subtypes: a systematic CT evaluation of 292 patients from the ASPIRE Registry. Thorax 2015; 70: 382-7.
104. HSU VM, CHUNG L, HUMMERS LK et al.: Development of pulmonary hypertension in a high-risk population with systemic sclerosis in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) cohort study. Semin Arthritis Rheum 2014; 44: 55-62.
105. VACCA A, MEUNE C, GORDON J et al.: Cardiac arrhythmias and conduction defects in systemic sclerosis. Rheumatology (Oxford) 2014; 53: 1172-7.
106. ALLANORE Y, MEUNE C: Clinical consequences of functional and pathological changes. Eular textbook on Systemic Sclerosis. BMJ.
107. RODRíGUEZ-REYNA TS, MORELOS-GUZMAN M, HERNáNDEZ-REYES P et al.: Assessment of myocardial fibrosis and microvascular damage in systemic sclerosis by magnetic resonance imaging and coronary angiotomography. Rheumatology (Oxford) 2015; 54: 647-54.
108. MORONCINI G, SCHICCHI N, POMPONIO G et al.: Myocardial perfusion defects in scleroderma detected by contrast-enhanced cardiovascular magnetic resonance. Radiol Med (Torino) 2014; 119: 885-94.
109. MEUNE C, AVOUAC J, AISSOU L, ALLANORE Y: Systemic sclerosis-related acute myocardial infarction: definition. Am J Med 2014; 127: e37.
110. SORIANO A, AFELTRA A, SHOENFELD Y: Is atherosclerosis accelerated in systemic sclerosis? Novel insights. Curr Opin Rheumatol 2014; 26: 653-7.
111. DOMSIC RT, DEZFULIAN C, SHOUSHTARI A et al.: Endothelial dysfunction is present only in the microvasculature and microcirculation of early diffuse systemic sclerosis patients. Clin Exp Rheumatol 2014; 32 (Suppl. 86): S154-60.
112. AGOSTON G, GARGANI L, MIGLIORANZA MH et al.: Left atrial dysfunction detected by speckle tracking in patients with systemic sclerosis. Cardiovasc Ultrasound 2014; 12: 30.
113. EICHER J-C, BERTHIER S, AHO LS, LORCERIE B, BONNOTTE B, LAURENT G: Measurement of interatrial dyssynchrony using tissue Doppler imaging predicts functional capacity and cardiac involvement in systemic sclerosis. Clin Exp Rheumatol 2014; 32 (Suppl. 86): S171-6.
114. KöLTO G, VUOLTEENAHO O, SZOKODI I et al.: Prognostic value of N-terminal natriuretic peptides in systemic sclerosis: a single centre study. Clin Exp Rheumatol 2014; 32 (Suppl. 86): S75-81.
115. LEPRI G, GUIDUCCI S, BELLANDO-RANDONE S et al.: Evidence for oesophageal and anorectal involvement in very early systemic sclerosis (VEDOSS): report from a single VEDOSS/EUSTAR centre. Ann Rheum Dis 2015; 74: 124-8.
116. NAGARAJA V, MCMAHAN ZH, GETZUG T, KHANNA D: Management of gastrointestinal involvement in scleroderma. Curr Treat Options Rheumatol 2015; 1: 82-105.
117. HANSI N, THOUA N, CARULLI M et al.: Consensus best practice pathway of the UK scleroderma study group: gastrointestinal manifestations of systemic sclerosis. Clin Exp Rheumatol 2014; 32 (Suppl. 86): S214-21.
118. CEREDA E, CODULLO V, KLERSY C et al.: Disease-related nutritional risk and mortality in systemic sclerosis. Clin Nutr Edinb Scotl 2014; 33: 558-61.
119. CHUNLERTRITH K, NOIPRASIT A, FOOCHAROEN C et al.: GERD questionnaire for diagnosis of gastroesophageal reflux disease in systemic sclerosis. Clin Exp Rheumatol 2014; 32 (Suppl. 86): S98-102.
120. KHANNA D, HAYS RD, MARANIAN P et al.: Reliability and validity of the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument. Arthritis Rheum 2009; 61: 1257-63.
121. BARON M, HUDSON M, STEELE R, LO E, Canadian Scleroderma Research Group: Validation of the UCLA Scleroderma Clinica Trial Gastrointestinal Tract Instrument version 2.0 for systemic sclerosis. J Rheumatol 2011; 38: 1925-30.
122. NAGARAJA V, HAYS RD, KHANNA PP et al.: Construct validity of the Patient-Reported Outcomes Measurement Information System gastrointestinal symptom scales in systemic sclerosis. Arthritis Care Res 2014; 66: 1725-30.
123. BAE S, ALLANORE Y, COUSTET B, MARANIAN P, KHANNA D: Development and validation of French version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument. Clin Exp Rheumatol 2011; 29 (Suppl. 65): 15-21.
124. MEIJS J, PORS D, VLIET VLIELAND TPM, HUIZINGA TWJ, SCHOUFFOER AA: Translation, cross-cultural adaptation, and validation of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument (SCTC GIT) 2.0 into Dutch. Clin Exp Rheumatol 2014; 32 (Suppl. 86): S41-8.
125. TAUBER M, AVOUAC J, BENAHMED A et al.: Prevalence and predictors of small intestinal bacterial overgrowth in systemic sclerosis patients with gastrointestinal symptoms. Clin Exp Rheumatol 2014; 32 (Suppl. 86): S82-7.
126. MATHEWS JD, FORSYTHE AV, BRADY Z et al.: Cancer risk in 680,000 people exposed to computed tomography scans in childhood or adolescence: data linkage study of 11 million Australians. BMJ 2013; 346: f2360.
127. PICANO E, SEMELKA R, RAVENEL J, MATUCCI-CERINIC M: Rheumatological diseases and cancer: the hidden variable of radiation exposure. Ann Rheum Dis 2014; 73: 2065-8.
128. COLACI M, GIUGGIOLI D, VACCHI C et al.: Breast cancer in systemic sclerosis: results of a cross-linkage of an Italian Rheumatologic Center and a population-based Cancer Registry and review of the literature. Autoimmun Rev 2014; 13: 132-7.
129. SHAH AA, HUMMERS LK, CASCIOLA-ROSEN L, VISVANATHAN K, ROSEN A, WIGLEY FM: Examination of autoantibody status and clinical features associated with cancer risk and cancer-associated scleroderma. Arthritis Rheumatol (Hoboken NJ.) 2015; 67: 1053-61.
130. LI W, SHI Q, WANG W, LIU J, LI Q, HOU F: Calcium channel blockers and risk of breast cancer: a meta-analysis of 17 observational studies. PloS One 2014; 9: e105801.
131. BERNAL-BELLO D, GARCíA de TENA J, SIMEóN-AZNAR C, FONOLLOSA-PLA V: Systemic sclerosis, breast cancer and calcium channel blockers: a new player on the scene? Autoimmun Rev 2014; 13: 880-1.
132. DESAI CS, LEE DC, SHAH SJ: Systemic sclerosis and the heart: current diagnosis and management. Curr Opin Rheumatol 2011; 23: 545-54.
133. IUDICI M, MORONCINI G, CIPRIANI P, GIACOMELLI R, GABRIELLI A, VALENTINI G: Where are we going in the management of interstitial lung disease in patients with systemic sclerosis? Autoimmun Rev 2015; 14: 575-8.
134. CAPPELLI S, BELLANDO-RANDONE S, GUIDUCCI S, MATUCCI-CERINIC M: Is immunosuppressive therapy the anchor treatment to achieve remission in systemic sclerosis? Rheumatology (Oxford) 2014; 53: 975-87.
135. BOSELLO SL, De LUCA G, RUCCO M et al.: Long-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis. Semin Arthritis Rheum 2015; 44: 428-36.
136. FRATICELLI P, GABRIELLI B, POMPONIO G et al.: Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study. Arthritis Res Ther 2014; 16: R144.
137. GORDON J, UDEH U, DOOBAY K et al.: Imatinib mesylate (Gleevec™) in the treatment of diffuse cutaneous systemic sclerosis: results of a 24-month open label, extension phase, single-centre trial. Clin Exp Rheumatol 2014; 32 (Suppl. 86): S189-93.
138. RICE LM, PADILLA CM, McLAUGHLIN SR et al.: Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients. J Clin Invest 2015; 125: 2795-807.
139. HOFFMANN-La ROCHE: A study of the efficacy and safety of tocilizumab in participants with systemic sclerosis (SSc) [focuSSced] In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2015-[cited 2015 Jul 16]. Available from: http://clinicaltrials.gov/show/NCT02453256NLMIdentifier:NCT02453256.
140. KHADKA A, SINGH BRASHIER DB, TEJUS A, SHARMA AK: Macitentan: An important addition to the treatment of pulmonary arterial hypertension. J Pharmacol Pharmacother 2015; 6: 53-7.
141. BAYER: Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis In: ClinicalTrials. gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2014-[2015 Jul 16]. Available from: https://clinicaltrials.gov/ct2/show/NCT02283762 NLM Identifier: NCT02283762.
142. CHUNG L, BALL K, YAQUB A, LINGALA B, FIORENTINO D: Effect of the endothelin type A-selective endothelin receptor antagonist ambrisentan on digital ulcers in patients with systemic sclerosis: results of a prospective pilot study. J Am Acad Dermatol 2014; 71: 400-1.
143. HACHULLA E, HATRON P-Y, CARPENTIER P et al.: Efficacy of sildenafil on ischaemic digital ulcer healing in systemic sclerosis: the placebo-controlled SEDUCE study. Ann Rheum Dis 2015 May 20 [Epub ahead of print].
144. CIPRIANI P, RUSCITTI P, GIACOMELLI R: Stem cell therapies for systemic sclerosis. Br J Haematol 2015; 168: 328-37.
145. KHANNA D, GEORGES GE, COURIEL DR: Autologous hematopoietic stem cell therapy in severe systemic sclerosis: ready for clinical practice? JAMA 2014; 311: 2485-7.
146. CANTARINI L, RIGANTE D, VITALE A et al.: Intravenous immunoglobulins (IVIG) in systemic sclerosis: a challenging yet promising future. Immunol Res 2015; 61: 326-37.
147. Georgetown University, CSL Behring. IVIG Treatment in Systemic Sclerosis In: ClinicalTrials. gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2013-[cited 2015 Jul 16]. Available from: https://clinicaltrials.gov/ct2/show/NCT01785056 NLM Identifier: NCT01785056.